Loading
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (41 ops.)
Latest filing published 19 Jan 2023 for PepGen Inc., €47k.
Filing timeline
BuySaleLaurie Keating
Insider track record
Disclosed buys
4
Disclosed sells
41
Signal history
Closed purchases
Market purchases
4
Positive at T+90
75%
Median T+90
+14.6%
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -60.3%Entry US$17.29 · Close at T+365 US$6.87
- +90.4%Entry US$4.70 · Close at T+365 US$8.95
- -76.3%Entry US$26.97 · Close at T+365 US$6.40
- +44.4%Entry US$69.70 · Close at T+365 US$100.65
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Laurie Keating: trading record in brief
Laurie Keating combines buying and selling in a record of 86 filings. At Alnylam Pharmaceuticals, Inc., under the title EVP, Chief Legal Officer (83 filings), the 40 sales total EUR 26,710,100, a median of EUR 433,770; two of them, EUR 2,220,701 and EUR 2,014,158, are dated July 13, 2020, and a third, EUR 1,596,439, August 5, 2021.
Four purchases, worth EUR 842,128 in all, are also recorded: EUR 672,705 at Alnylam on May 30, 2017, EUR 88,462 at Immuneering Corp on August 3, 2021 and EUR 47,432 at PepGen Inc. on May 6, 2022. They are 9% of the open-market trades. There are also 25 option exercises, 11 grants and 6 filings of another nature.
The peak comes in 2020 (28 filings), then 2021 (24). No filing falls in the last twelve months. The count of trades by Keating within 30 days of colleagues at Alnylam Pharmaceuticals, Inc. is 30, 27 and 19. Same direction: 30, 26 and 19. Colleagues in order: Yvonne Greenstreet, Akshay Vaishnaw and John Maraganore.
Companies and markets linked to Laurie Keating
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations86 total
4,166 shares@ US$12.00100.0% of flowCommon StockSEC:0001127602-23-001831:0
Canonical exit: 4 Aug 2022 (T+90)
7,000 shares@ US$5.0027.5% of flowClass A Common StockSEC:0001415889-22-005150:0
Canonical exit: 14 Aug 2022 (T+90)
2,124 shares@ US$88.950.4% of flowCommon StockSEC:0001735276-21-000079:1
10,000 shares@ US$188.953.9% of flowCommon StockSEC:0001735276-21-000079:2
7,876 shares@ US$88.9562.9% of flowCommon StockSEC:0001735276-21-000079:0
7,000 shares@ US$15.0072.5% of flowClass A Common StockSEC:0001104659-21-099736:0
Canonical exit: 1 Nov 2021 (T+90)
5,000 shares@ US$88.950.9% of flowCommon StockSEC:0001735276-21-000053:1
1,812 shares@ US$179.000.7% of flowCommon StockSEC:0001735276-21-000053:2
5,000 shares@ US$178.951.8% of flowCommon StockSEC:0001735276-21-000053:3
1,812 shares@ US$85.0013.8% of flowCommon StockSEC:0001735276-21-000053:0
1,734 shares@ US$154.0023.3% of flowCommon StockSEC:0001735276-21-000047:0
2,014 shares@ US$131.750.5% of flowCommon StockSEC:0001735276-21-000038:1
75 shares@ US$134.420.0% of flowCommon StockSEC:0001735276-21-000038:2
4,518 shares0Common StockSEC:0001735276-21-000038:0
106 shares@ US$153.540.0% of flowCommon StockSEC:0001735276-21-000011:2
1,857 shares@ US$156.000.6% of flowCommon StockSEC:0001735276-21-000011:1
4,166 shares0Common StockSEC:0001735276-21-000011:0
3,027 shares@ US$77.400.5% of flowCommon StockSEC:0001735276-21-000006:0
6,000 shares@ US$85.001.0% of flowCommon StockSEC:0001735276-21-000006:1
5,000 shares@ US$169.001.7% of flowCommon StockSEC:0001735276-21-000006:2
1,027 shares@ US$174.000.4% of flowCommon StockSEC:0001735276-21-000006:4
758 shares@ US$154.000.2% of flowCommon StockSEC:0001735276-21-000004:0
1,941 shares@ US$42.220.2% of flowCommon StockSEC:0001735276-21-000004:1
13,000 shares@ US$77.402.0% of flowCommon StockSEC:0001735276-21-000004:2
11,941 shares@ US$159.003.8% of flowCommon StockSEC:0001735276-21-000004:3
25 of 86 declarations
